A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer

Published:2009-04 Issue:4 Volume:20 Page:281-286
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Zhao Jian Guo,Qiu Feng,Xiong Jian Ping,Zhang Ling,Xiang Xiao Jun,Yu Feng,Yan Jun,Zhan Zhen Yu,Feng Miao

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference33 articles.

1. Global Cancer Statistics 2002;Parkin;CA Cancer J Clin,2005

2. Underrepresentation of patients 65 years of age or older in cancer-treatment trials;Hutchins;N Engl J Med,1999

3. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration;Talarico;J Clin Oncol,2004

4. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data;Wagner;J Clin Oncol,2006

5. Randomized trial comparing epirubicin, cisplatin, and 5-fluorouracil versus 5-fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer;Webb;J Clin Oncol,1997

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature;Cancer Treatment Reviews;2021-11

2. Tumors: Gastrointestinal Cancers;Encyclopedia of Gerontology and Population Aging;2021

3. Tumors: Gastrointestinal Cancers;Encyclopedia of Gerontology and Population Aging;2021

4. Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX;Frontiers in Oncology;2020-12-23

5. A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy;Journal of Cancer Research and Therapeutics;2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3